Apixaban in atrial fibrillation: Does predicted risk matter?

The Lancet

Volumn 380, Issue 9855, 2012, Pages 1718-1720

  Vassiliou, Vassilis S ^a   Flynn, Paul D ^b  

^a St John's Innovation Centre   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DRUG COST; DRUG SAFETY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; NOTE; PREDICTION; PRIORITY JOURNAL; THERAPY EFFECT; THROMBOEMBOLISM;

EID: 84869090901     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61673-0     Document Type: Note

References (9)

1. Schofield FW. A brief account of a disease in cattle simulating hemorrhagic septicemia due to feeding sweet clover. Can Vet Rec 1922; 3: 74-78.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
3. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc 1998; 46: 1423-24.
4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 135: 981-92.
5. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012; published online Oct 2. http://dx.doi.org/10.1016/S0140- 6736(12)60986-6.
6. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011; 155: 653-59.
7. Wurster MW. Dabigatran use in the real world: preliminary results of a prospective trial comparing outcomes with dabigatran and warfarin therapy. Proceedings of the Thrombosis and Hemostasis summit of North America: research abstracts. Am J Hematol 2012; 87 (suppl): S146-S200 (abstr).
8. Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32: 2282-89.
9. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of the new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 488-97.